Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Halofenate

Halcinonide, 187 Halofenate, 80, 102 Haloform reaction, 88 Haloprogesterone, 173 Hepzidine, 222 Heroin, 315 Heteronium bromide, 72 Heterosteroids, 139-142 Hexobendine, 92 Histamine,... [Pg.1012]

Netoglitazone is an insulin sensitizer currently in Phase II clinical trials. It is able to modulate both PPAR-a and PPAR-y subtypes of peroxisome proliferator-activated receptor (Phase ll). Metaglidasen (MBX-102) is the (—)-enantiomer of the NSAID halofenate. This selective PPAR-y nuclear receptor agonist is being evaluated (Phase II) as an insulin sensitizer. It is structurally different from the currently marketed glitazones (Figure 8.84). ... [Pg.332]

Compound 43 which was of particular interest, showed a marked inhibition of drug metabolizing enzymes in the liver. The question of whether these structures, similar to halofenate 6, also possess comparable properties with regard to the lowering of hyperuricaemia, has not yet been elucidated. [Pg.119]

The class of a-aryloxy hydratropic acid derivatives (see Table 4) combines the characteristics of the clofibrate and the halofenate structure. Surprisingly, this slight modification of the basic structure caused a striking increase in activity. Compound 47, structurally most closely related to clofibrate, showed a spectrum of activity, which was superior to that of clofibrate (factor 5—10). Impressive also was the higher activity of compound 53 against Su-13.437 2. The advantage of compounds 48-52 was similarly clear. Several representatives selected from this series were prepared for a clinical trial. [Pg.119]

Halofenate Phenytoin unbound fraction Altered relation between total phenytoin concentration and effect Displacement from plasma protein binding sites... [Pg.294]

Clinical studies confirmed halofenate to be an effective hypotriglyceridemic and hypouricemic agent. B H Recent mechanism of action studies (earlier investigations were reviewed recently1 8) demonstrated... [Pg.192]

Halofenic acid is a SPPARM that functions primarily as a partial agonist characterized by the differential recruitment of PPAR cofactors, i.e. displacement of corepressors [NCoR and silencing mediator for retinoid and thyroid receptors (SMRT)] and inefficient recruitment of coactivators [cAMP response element binding protein (CREB) binding protein (CBP) and TRAP220] [73]. When dosed orally to diabetic mice and rats as the acetamidoethyl ester, halofenic acid produces insulin sensitization comparable to rosiglitazone without increases in body weight. [Pg.380]

Halofenate is a selective peroxisome proliferator-activated receptor y modulator with antidiabetic activity. Diabetes, 55, 2523-2533. [Pg.386]

Jain AK, Ryan JR, McMahon FG. Potentiation of h3fpoglycemic effect of sulfonylureas by halofenate. NEnglJMed 915) 293,1283-6. [Pg.490]

W.S. Aronow, P.R. Harding, M. Khursheed, J.S. Vangrow and N.P. Papageorges. Effect of halofenate on serum uric acid. Clin. Pharmacol. Therap. 1 371-373 (1973) ... [Pg.132]

Salicylates (large doses) Sulfinpyrazone Probenecid Phenylbutazone X-ray contrast agents Chlorprothixine 6-azauridine Halofenate Benzbromarone... [Pg.329]

See other pages where Halofenate is mentioned: [Pg.269]    [Pg.239]    [Pg.80]    [Pg.81]    [Pg.102]    [Pg.103]    [Pg.495]    [Pg.499]    [Pg.586]    [Pg.587]    [Pg.608]    [Pg.609]    [Pg.1001]    [Pg.1005]    [Pg.1587]    [Pg.332]    [Pg.103]    [Pg.103]    [Pg.104]    [Pg.106]    [Pg.119]    [Pg.257]    [Pg.179]    [Pg.139]    [Pg.128]    [Pg.193]    [Pg.73]    [Pg.278]    [Pg.279]    [Pg.130]   
See also in sourсe #XX -- [ Pg.80 , Pg.102 ]

See also in sourсe #XX -- [ Pg.2 , Pg.80 , Pg.102 ]

See also in sourсe #XX -- [ Pg.332 ]

See also in sourсe #XX -- [ Pg.128 ]

See also in sourсe #XX -- [ Pg.83 , Pg.192 ]

See also in sourсe #XX -- [ Pg.176 , Pg.185 ]

See also in sourсe #XX -- [ Pg.331 ]



SEARCH



Halofenic acid

© 2024 chempedia.info